Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
2.
Circ Res ; 122(4): 560-567, 2018 02 16.
Article in English | MEDLINE | ID: mdl-29321129

ABSTRACT

RATIONALE: Animal models have been used to explore factors that regulate atherosclerosis. More recently, they have been used to study the factors that promote loss of macrophages and reduction in lesion size after lowering of plasma cholesterol levels. However, current animal models of atherosclerosis regression require challenging surgeries, time-consuming breeding strategies, and methods that block liver lipoprotein secretion. OBJECTIVE: We sought to develop a more direct or time-effective method to create and then reverse hypercholesterolemia and atherosclerosis via transient knockdown of the hepatic LDLR (low-density lipoprotein receptor) followed by its rapid restoration. METHODS AND RESULTS: We used antisense oligonucleotides directed to LDLR mRNA to create hypercholesterolemia in wild-type C57BL/6 mice fed an atherogenic diet. This led to the development of lesions in the aortic root, aortic arch, and brachiocephalic artery. Use of a sense oligonucleotide replicating the targeted sequence region of the LDLR mRNA rapidly reduced circulating cholesterol levels because of recovery of hepatic LDLR expression. This led to a decrease in macrophages within the aortic root plaques and brachiocephalic artery, that is, regression of inflammatory cell content, after a period of 2 to 3 weeks. CONCLUSIONS: We have developed an inducible and reversible hepatic LDLR knockdown mouse model of atherosclerosis regression. Although cholesterol reduction decreased early en face lesions in the aortic arches, macrophage area was reduced in both early and late lesions within the aortic sinus after reversal of hypercholesterolemia. Our model circumvents many of the challenges associated with current mouse models of regression. The use of this technology will potentially expedite studies of atherosclerosis and regression without use of mice with genetic defects in lipid metabolism.


Subject(s)
Atherosclerosis/genetics , Disease Models, Animal , Gene Knockdown Techniques/methods , Receptors, LDL/genetics , Animals , Aorta/pathology , Atherosclerosis/blood , Atherosclerosis/pathology , Cholesterol/blood , Female , Male , Mice , Mice, Inbred C57BL , Oligonucleotides, Antisense/genetics , Receptors, LDL/metabolism
3.
Arterioscler Thromb Vasc Biol ; 39(10): 1967-1985, 2019 10.
Article in English | MEDLINE | ID: mdl-31434492

ABSTRACT

OBJECTIVE: Fatty acid uptake and oxidation characterize the metabolism of alternatively activated macrophage polarization in vitro, but the in vivo biology is less clear. We assessed the roles of LpL (lipoprotein lipase)-mediated lipid uptake in macrophage polarization in vitro and in several important tissues in vivo. Approach and Results: We created mice with both global and myeloid-cell specific LpL deficiency. LpL deficiency in the presence of VLDL (very low-density lipoproteins) altered gene expression of bone marrow-derived macrophages and led to reduced lipid uptake but an increase in some anti- and some proinflammatory markers. However, LpL deficiency did not alter lipid accumulation or gene expression in circulating monocytes nor did it change the ratio of Ly6Chigh/Ly6Clow. In adipose tissue, less macrophage lipid accumulation was found with global but not myeloid-specific LpL deficiency. Neither deletion affected the expression of inflammatory genes. Global LpL deficiency also reduced the numbers of elicited peritoneal macrophages. Finally, we assessed gene expression in macrophages from atherosclerotic lesions during regression; LpL deficiency did not affect the polarity of plaque macrophages. CONCLUSIONS: The phenotypic changes observed in macrophages upon deletion of Lpl in vitro is not mimicked in tissue macrophages.


Subject(s)
Atherosclerosis/metabolism , Hyperlipoproteinemia Type I/metabolism , Lipoprotein Lipase/metabolism , Macrophage Activation/genetics , Animals , Atherosclerosis/pathology , Cells, Cultured , Disease Models, Animal , Humans , Hyperlipoproteinemia Type I/pathology , Macrophages/metabolism , Mice , Mice, Knockout , Myeloid Progenitor Cells/metabolism , Myeloid Progenitor Cells/pathology , Role , Sensitivity and Specificity , Triglycerides/metabolism
4.
Arterioscler Thromb Vasc Biol ; 38(9): 2207-2216, 2018 09.
Article in English | MEDLINE | ID: mdl-30354257

ABSTRACT

Objective- SGLT2 (sodium-glucose cotransporter 2) inhibition in humans leads to increased levels of LDL (low-density lipoprotein) cholesterol and decreased levels of plasma triglyceride. Recent studies, however, have shown this therapy to lower cardiovascular mortality. In this study, we aimed to determine how SGLT2 inhibition alters circulating lipoproteins. Approach and Results- We used a mouse model expressing human CETP (cholesteryl ester transfer protein) and human ApoB100 (apolipoprotein B100) to determine how SGLT2 inhibition alters plasma lipoprotein metabolism. The mice were fed a high-fat diet and then were made partially insulin deficient using streptozotocin. SGLT2 was inhibited using a specific antisense oligonucleotide or canagliflozin, a clinically available oral SGLT2 inhibitor. Inhibition of SGLT2 increased circulating levels of LDL cholesterol and reduced plasma triglyceride levels. SGLT2 inhibition was associated with increased LpL (lipoprotein lipase) activity in the postheparin plasma, decreased postprandial lipemia, and faster clearance of radiolabeled VLDL (very-LDL) from circulation. Additionally, SGLT2 inhibition delayed turnover of labeled LDL from circulation. Conclusions- Our studies in diabetic CETP-ApoB100 transgenic mice recapitulate many of the changes in circulating lipids found with SGLT2 inhibition therapy in humans and suggest that the increased LDL cholesterol found with this therapy is because of reduced clearance of LDL from the circulation and greater lipolysis of triglyceride-rich lipoproteins. Most prominent effects of SGLT2 inhibition in the current mouse model were seen with antisense oligonucleotides-mediated knockdown of SGLT2.


Subject(s)
Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/drug therapy , Lipoproteins, LDL/blood , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Triglycerides/blood , Adipose Tissue/metabolism , Angiopoietin-Like Protein 4/genetics , Animals , Blood Glucose/metabolism , Down-Regulation , Fatty Acids, Nonesterified/blood , Gene Expression , Male , Mice, Inbred C57BL , Mice, Transgenic , Muscle, Skeletal/metabolism , Myocardium/metabolism , RNA, Messenger/genetics , Sodium-Glucose Transporter 2 Inhibitors/pharmacology
5.
J Lipid Res ; 58(6): 1132-1142, 2017 06.
Article in English | MEDLINE | ID: mdl-28404638

ABSTRACT

Lipid accumulation is a pathological feature of every type of kidney injury. Despite this striking histological feature, physiological accumulation of lipids in the kidney is poorly understood. We studied whether the accumulation of lipids in the fasted kidney are derived from lipoproteins or NEFAs. With overnight fasting, kidneys accumulated triglyceride, but had reduced levels of ceramide and glycosphingolipid species. Fasting led to a nearly 5-fold increase in kidney uptake of plasma [14C]oleic acid. Increasing circulating NEFAs using a ß adrenergic receptor agonist caused a 15-fold greater accumulation of lipid in the kidney, while mice with reduced NEFAs due to adipose tissue deficiency of adipose triglyceride lipase had reduced triglycerides. Cluster of differentiation (Cd)36 mRNA increased 2-fold, and angiopoietin-like 4 (Angptl4), an LPL inhibitor, increased 10-fold. Fasting-induced kidney lipid accumulation was not affected by inhibition of LPL with poloxamer 407 or by use of mice with induced genetic LPL deletion. Despite the increase in CD36 expression with fasting, genetic loss of CD36 did not alter fatty acid uptake or triglyceride accumulation. Our data demonstrate that fasting-induced triglyceride accumulation in the kidney correlates with the plasma concentrations of NEFAs, but is not due to uptake of lipoprotein lipids and does not involve the fatty acid transporter, CD36.


Subject(s)
Fasting/blood , Fasting/metabolism , Fatty Acids, Nonesterified/blood , Kidney/metabolism , Triglycerides/metabolism , Animals , Female , Male , Mice , Mice, Inbred C57BL , Oxidation-Reduction
6.
Arterioscler Thromb Vasc Biol ; 31(8): 1805-13, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21636809

ABSTRACT

OBJECTIVE: There are several pathways that mediate the aberrant metabolism of glucose and that might induce greater vascular damage in the setting of diabetes. The polyol pathway mediated by aldose reductase (AR) has been postulated to be one such pathway. However, it has been reported that AR reduces toxic lipid aldehydes and, under some circumstances, might be antiatherogenic. METHODS AND RESULTS: Atherosclerosis development was quantified in 2 lines of transgenic mice expressing human AR (hAR) crossed on the apolipoprotein E knockout background. The transgenes were used to increase the normally low levels of this enzyme in wild-type mice. Both generalized hAR overexpression and hAR expression via the Tie 2 promoter increased lesion size in streptozotocin diabetic mice. In addition, pharmacological inhibition of AR reduced lesion size. CONCLUSIONS: Although in some settings AR expression might reduce levels of toxic aldehydes, transgenic expression of this enzyme within the artery wall leads to greater atherosclerosis.


Subject(s)
Aldehyde Reductase/metabolism , Atherosclerosis/etiology , Diabetes Mellitus, Experimental/metabolism , Aldehyde Reductase/antagonists & inhibitors , Aldehyde Reductase/genetics , Animals , Atherosclerosis/genetics , Atherosclerosis/metabolism , Atherosclerosis/pathology , Base Sequence , Cell Line , DNA, Complementary/genetics , Diabetes Complications/etiology , Diabetes Complications/genetics , Diabetes Complications/metabolism , Diabetes Complications/pathology , Diabetes Mellitus, Experimental/genetics , Endothelial Cells/metabolism , Enzyme Inhibitors/pharmacology , Female , Gene Expression , Glucose/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , RNA, Small Interfering/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Vasodilation/physiology
7.
J Biol Chem ; 285(49): 37976-86, 2010 Dec 03.
Article in English | MEDLINE | ID: mdl-20852327

ABSTRACT

Lipids circulate in the blood in association with plasma lipoproteins and enter the tissues either after hydrolysis or as non-hydrolyzable lipid esters. We studied cardiac lipids, lipoprotein lipid uptake, and gene expression in heart-specific lipoprotein lipase (LpL) knock-out (hLpL0), CD36 knock-out (Cd36(-/-)), and double knock-out (hLpL0/Cd36(-/-)-DKO) mice. Loss of either LpL or CD36 led to a significant reduction in heart total fatty acyl-CoA (control, 99.5 ± 3.8; hLpL0, 36.2 ± 3.5; Cd36(-/-), 57.7 ± 5.5 nmol/g, p < 0.05) and an additive effect was observed in the DKO (20.2 ± 1.4 nmol/g, p < 0.05). Myocardial VLDL-triglyceride (TG) uptake was reduced in the hLpL0 (31 ± 6%) and Cd36(-/-) (47 ± 4%) mice with an additive reduction in the DKO (64 ± 5%) compared with control. However, LpL but not CD36 deficiency decreased VLDL-cholesteryl ester uptake. Endogenously labeled mouse chylomicrons were produced by tamoxifen treatment of ß-actin-MerCreMer/LpL(flox/flox) mice. Induced loss of LpL increased TG levels >10-fold and reduced HDL by >50%. After injection of these labeled chylomicrons in the different mice, chylomicron TG uptake was reduced by ∼70% and retinyl ester by ∼50% in hLpL0 hearts. Loss of CD36 did not alter either chylomicron TG or retinyl ester uptake. LpL loss did not affect uptake of remnant lipoproteins from ApoE knock-out mice. Our data are consistent with two pathways for fatty acid uptake; a CD36 process for VLDL-derived fatty acid and a non-CD36 process for chylomicron-derived fatty acid uptake. In addition, our data show that lipolysis is involved in uptake of core lipids from TG-rich lipoproteins.


Subject(s)
CD36 Antigens/metabolism , Cholesterol, VLDL/metabolism , Chylomicrons/metabolism , Fatty Acids/metabolism , Lipid Metabolism/physiology , Lipoprotein Lipase/metabolism , Lipoproteins, VLDL/metabolism , Myocardium/metabolism , Triglycerides/metabolism , Animals , Antineoplastic Agents, Hormonal/pharmacokinetics , CD36 Antigens/genetics , Cholesterol, VLDL/genetics , Chylomicrons/genetics , Fatty Acids/genetics , Lipid Metabolism/drug effects , Lipoprotein Lipase/genetics , Lipoproteins, VLDL/genetics , Mice , Mice, Knockout , Tamoxifen/pharmacology , Triglycerides/genetics
8.
J Clin Lipidol ; 15(1): 61-67, 2021.
Article in English | MEDLINE | ID: mdl-33191194

ABSTRACT

BACKGROUND: The adoption of low-carbohydrate diets can lead to weight loss in many patients. However, these now widespread diets also have the potential to exacerbate hypercholesterolemia. OBJECTIVE: The objective of this study is to display the potentially harmful effects of the ketogenic diet on cholesterol levels in patients with or without underlying hyperlipidemia. METHODS: We describe 5 patients who developed marked increases in plasma cholesterol on ketogenic diets and assessed whether they had a well-described underlying genetic hyperlipidemia. RESULTS: Three out of 5 patients had extraordinary increases of blood cholesterol levels to over 500 mg/dL. The other 2 patients more than doubled their low-density lipoprotein cholesterol levels on a ketogenic diet. One patient had an APOE E2/E2 genotype. A higher burden of common genetic polymorphisms was found in 2 patients, with no major mutations found. No potential genetic cause was seen in a fourth patient, and the fifth patient had no genetic testing. Three patients, including the one who was most hypercholesterolemic, had a marked reduction in cholesterol after reverting to a more liberal diet. One refused to change his diet but had a satisfactory low-density lipoprotein cholesterol reduction on ezetimibe. CONCLUSION: These cases should serve as a caution that high-fat low-carbohydrate diets have the potential to exacerbate or cause hypercholesterolemia in patients with or without underlying genetic hyperlipidemia.


Subject(s)
Diet, Ketogenic , Adult , Diet, Fat-Restricted , Humans , Male , Weight Loss
9.
J Clin Invest ; 128(10): 4329-4342, 2018 10 01.
Article in English | MEDLINE | ID: mdl-30047927

ABSTRACT

Movement of circulating fatty acids (FAs) to parenchymal cells requires their transfer across the endothelial cell (EC) barrier. The multiligand receptor cluster of differentiation 36 (CD36) facilitates tissue FA uptake and is expressed in ECs and parenchymal cells such as myocytes and adipocytes. Whether tissue uptake of FAs is dependent on EC or parenchymal cell CD36, or both, is unknown. Using a cell-specific deletion approach, we show that EC, but not parenchymal cell, CD36 deletion increased fasting plasma FAs and postprandial triglycerides. EC-Cd36-KO mice had reduced uptake of radiolabeled long-chain FAs into heart, skeletal muscle, and brown adipose tissue; these uptake studies were replicated using [11C]palmitate PET scans. High-fat diet-fed EC-CD36-deficient mice had improved glucose tolerance and insulin sensitivity. Both EC and cardiomyocyte (CM) deletion of CD36 reduced heart lipid droplet accumulation after fasting, but CM deletion did not affect heart glucose or FA uptake. Expression in the heart of several genes modulating glucose metabolism and insulin action increased with EC-CD36 deletion but decreased with CM deletion. In conclusion, EC CD36 acts as a gatekeeper for parenchymal cell FA uptake, with important downstream effects on glucose utilization and insulin action.


Subject(s)
CD36 Antigens/metabolism , Endothelial Cells/metabolism , Fatty Acids/metabolism , Myocardium/metabolism , Myocytes, Cardiac/metabolism , Animals , Biological Transport, Active/genetics , CD36 Antigens/genetics , Endothelial Cells/pathology , Fatty Acids/genetics , Glucose/genetics , Glucose/metabolism , Humans , Insulin Resistance , Mice , Mice, Knockout , Myocardium/pathology , Myocytes, Cardiac/pathology , Organ Specificity
10.
Forensic Sci Int ; 280: 87-94, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28965000

ABSTRACT

In this study we demonstrate the use of Direct Analysis in Real Time Mass Spectrometry (DART) as a powerful tool for detection of nonoxynol in vaginal fluid post contact with a condom, enabling rapid tracing and added evidences in sexual assault crimes. Vaginal fluid was sampled using cotton swabs and glass rods and measured directly with DART. Sample preparation using water, hexane, methanol, and dichloromethane extraction, was explored for comparison and optimization of signals. Nonoxynol was detected up to eight hours after sampling. Optimal sampling conditions and mass spectrometry parameters are reported and discussed.


Subject(s)
Cervix Mucus/chemistry , Condoms , Lubricants/chemistry , Nonoxynol/analysis , Spermatocidal Agents/analysis , Female , Forensic Medicine , Humans , Male , Mass Spectrometry/methods , Specimen Handling , Time Factors
11.
Diabetes ; 57(6): 1674-82, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18346984

ABSTRACT

OBJECTIVE: Patients with diabetes often have dyslipidemia and increased postprandial lipidmia. Induction of diabetes in LDL receptor (Ldlr(-/-)) knockout mice also leads to marked dyslipidemia. The reasons for this are unclear. RESEARCH DESIGN AND METHODS: We placed Ldlr(-/-) and heterozygous LDL receptor knockout (Ldlr(+/-)) mice on a high-cholesterol (0.15%) diet, induced diabetes with streptozotocin (STZ), and assessed reasons for differences in plasma cholesterol. RESULTS: STZ-induced diabetic Ldlr(-/-) mice had plasma cholesterol levels more than double those of nondiabetic controls. Fast-performance liquid chromatography and ultracentrifugation showed an increase in both VLDL and LDL. Plasma VLDL became more cholesterol enriched, and both VLDL and LDL had a greater content of apolipoprotein (apo)E. In LDL the ratio of apoB48 to apoB100 was increased. ApoB production, assessed using [(35)S]methionine labeling in Triton WR1339-treated mice, was not increased in fasting STZ-induced diabetic mice. Similarly, postprandial lipoprotein production was not increased. Reduction of cholesterol in the diet to normalize the amount of cholesterol intake by the control and STZ-induced diabetic animals reduced plasma cholesterol levels in STZ-induced diabetic mice, but plasma cholesterol was still markedly elevated compared with nondiabetic controls. LDL from STZ-induced diabetic mice was cleared from the plasma and trapped more rapidly by livers of control mice. STZ treatment reduced liver expression of the proteoglycan sulfation enzyme, heparan sulfate N-deacetylase/N-sulfotrasferase-1, an effect that was reproduced in cultured hepatocytyes by a high glucose-containing medium. CONCLUSIONS: STZ-induced diabetic, cholesterol-fed mice developed hyperlipidemia due to a non-LDL receptor defect in clearance of circulating apoB-containing lipoproteins.


Subject(s)
Cholesterol/blood , Diabetes Mellitus, Experimental/blood , Lipids/blood , Lipoproteins/blood , Receptors, LDL/deficiency , Triglycerides/blood , Animals , Apolipoproteins B/blood , Apolipoproteins E/blood , Blood Glucose/metabolism , Cholesterol, Dietary , Crosses, Genetic , Diabetes Mellitus, Experimental/physiopathology , Dyslipidemias/genetics , Liver/physiopathology , Liver Neoplasms , Liver Neoplasms, Experimental , Mice , Mice, Inbred C57BL , Mice, Knockout , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL